
ZAP Surgical Announces First ZAP-X Gyroscopic Radiosurgery
SAN CARLOS, Calif.--(BUSINESS WIRE)--ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced the first patient treatments using its ZAP-X® Gyroscopic Radiosurgery® platform in Latin America. Located in Neuland, Boquerón, Paraguay, Radioterapia Concordia (www.saludconcordia.com) has officially commenced clinical use, marking a major milestone in the decentralization of state-of-the-art brain tumor care across the region.
In its first day of operation, four patients received next-generation stereotactic radiosurgery (SRS) with ZAP-X® for a range of intracranial conditions, including meningioma, acoustic neuroma, trigeminal neuralgia, and arteriovenous malformation (AVM).
Historically, patients in the central regions of Latin America have had limited or no access to modern SRS, often requiring travel to large metropolitan hubs like Buenos Aires, São Paulo, or Santiago. Radioterapia Concordia now offers these advanced treatments locally, helping bridge a longstanding healthcare gap for rural communities.
'People in rural areas deserve to receive world-class medical care where they live, from people they understand, and at a fair price,' said Prof. Dr. Peter Douglas Klassen, Founder of Saludconcordia SA. 'With ZAP-X, we are bringing the most advanced SRS capabilities to communities that have long been underserved.'
The creation of Radioterapia Concordia is further bolstered by its strategic location along the Bi-Oceanic Corridor—a transformative infrastructure project linking Brazil, Paraguay, Argentina, and Chile to improve regional access and trade. The new cancer center also benefits from its collaborative relationship with ZAP-X Zentrum Lingen in Germany, home to Europe's first ZAP-X system.
'This is more than just a technology deployment—it's a movement toward cooperative medicine,' said MBA MSc Edelgard Loewen, Case Manager at ZAP-X Zentrum Lingen. 'We're witnessing a new model emerge in Latin America—one that rises above the limitations of national and purely private healthcare systems to prioritize patients through altruistic, turnkey cancer care.'
As an alternative to open brain surgery, stereotactic radiosurgery is a non-invasive, outpatient procedure used to treat many primary and metastatic brain tumors, as well as other disorders of the head and neck. Unlike traditional surgery however, SRS does not require incisions or anesthesia, and patients often return to normal activities the same day.
The ZAP-X system is renowned for its unique gyroscopic design, which enables the delivery of radiosurgical beams from thousands of unique angles. This approach enhances the ability to concentrate radiation precisely on the tumor while minimizing dose to surrounding healthy brain tissue—an important factor in preserving cognitive function.
ZAP-X is also the first and only vault-free SRS system, removing the need for costly shielded treatment rooms. Additionally, by utilizing a modern linear accelerator, ZAP-X eliminates the use of Cobalt-60, avoiding the exorbitant costs and regulatory burdens tied to radioactive isotopes.
For more information about ZAP Surgical and the ZAP-X system, visit www.zapsurgical.com.
About ZAP Surgical Systems, Inc.
ZAP Surgical Systems, Inc. designs and manufactures the ZAP-X® Gyroscopic Radiosurgery® platform. ZAP was founded in 2014 by Dr. John R. Adler, Emeritus Dorothy & TK Chan Professor of Neurosurgery and Radiation Oncology at Stanford University. Dr. Adler is also renowned as the inventor of the CyberKnife ® system and founder of Accuray, Inc. The ZAP-X platform incorporates a unique vault-free design that typically eliminates the need for costly shielded treatment rooms. ZAP-X also utilizes a modern linear accelerator to eliminate legacy use of Cobalt-60. Learn more at ZAP Surgical and follow us on LinkedIn.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
37 minutes ago
- Business Wire
Simplify Healthcare Launches Xperience1™: A Next-Generation Platform for Benefits Inquiry Management, Powered by Domain-Rich AI
AURORA, Ill.--(BUSINESS WIRE)-- Simplify Healthcare, a recognized leader in enterprise software solutions for Payers, today announced Xperience1™, a groundbreaking solution designed to transform the benefits inquiry experience for health plan members, providers, brokers, and other stakeholders. This next-generation CX platform delivers clear, real-time, plain-language responses to complex benefit questions—across all channels and user roles. Built on the trusted Simplify Health Cloud™, Xperience1™ unifies the strengths of the company's flagship platforms, Service1™ and Experience1™, into one intelligent, AI-powered customer experience platform. It enables payers to streamline and elevate benefits communication across the entire member journey—from plan shopping and enrollment to customer service and self-service. 'Xperience1™ is the natural next step in our mission to transform how healthcare consumers understand, navigate, and experience their benefits,' said Ashish Desai, EVP and GM, Xperience1™, Simplify Healthcare. 'It delivers measurable business impact by significantly reducing call duration, improving first call resolution (FCR), and ensuring clear, consistent, member-friendly communication.' Unlike generic GenAI-based solutions that are prone to hallucinations, Xperience1™ is built on a robust architecture featuring a sophisticated domain-rich data foundation, intelligent content management, an interactive AI framework, and a built-in health literacy model. These capabilities enable it to provide accurate, context-aware, and curated responses—minimizing the risk of misinformation. ' With Xperience1™, we're going further—not starting over,' added Mohammed Vaid, CEO and Chief Solution Architect, Simplify Healthcare. ' We've reimagined two trusted solutions into one unified platform, delivering on our promise to bring clarity to complexity.' The launch of Xperience1™ underscores Simplify Healthcare's commitment to innovation and its mission to simplify the healthcare experience. To learn more about Xperience1™, visit About Simplify Healthcare Simplify Healthcare helps payers achieve growth and operational efficiency through its industry-leading platform, proven processes, and deep expertise. Founded in 2008, the company tackles some of the most complex challenges in healthcare by connecting the front, middle, and back office through a platform-centric, payer-focused approach.


Business Wire
an hour ago
- Business Wire
Pioneering precision: GE HealthCare aims to elevate clinical care through total body PET/CT technology with Stanford Medicine
CHICAGO--(BUSINESS WIRE)--Building on a collaboration that spans more than three decades, GE HealthCare has renewed its research collaboration with Stanford Medicine – with one of their key intentions being the development and research of innovative total body PET/CT technology. i This effort is expected to explore new clinical pathways and help enhance patient outcomes through innovative imaging solutions. 'This technology is designed to offer a level of sensitivity and spatial resolution that can change how we design and conduct molecular imaging studies,' says Dr. Andrei Iagaru, Division Chief of Nuclear Medicine and Molecular Imaging, Stanford Medicine. Share 'PET/CT has revolutionized the way we understand and treat disease by allowing us to visualize biological processes at the cellular level,' explains Dr. Quynh-Thu Le, interim Chair of the Department of Radiology, Stanford Medicine. 'With total body PET/CT, we can explore new frontiers. Not only do we expect it will be faster, but we also believe it will fundamentally expand what is possible in translational research.' Molecular imaging – and specifically the utilization of PET/CT scanners – offers opportunities for precision care across various disease states. It supports theranostics in oncology for advanced prostate cancer treatment, helps streamline radiation oncology workflows, aids in beta amyloid imaging for Alzheimer's evaluation and monitoring, and assists in myocardial perfusion evaluation for diagnosing coronary artery disease. Unlike other imaging procedures, PET/CT technology visualizes, characterizes, and quantifies biological processes at the cellular level, aiding in early disease identification, detailed assessment, and treatment planning. It is a non-invasive solution, providing critical insights that help enhance patient care and can support accelerated drug development. 'This technology is designed to offer a level of sensitivity and spatial resolution that can change how we design and conduct molecular imaging studies,' adds Dr. Andrei Iagaru, Division Chief of Nuclear Medicine and Molecular Imaging, Stanford Medicine. 'For example, such technological characteristics can create opportunities to reduce anesthesia use in pediatric imaging by dramatically shortening scan times and enable the exploration of dual-tracer studies and early diagnosis with far greater precision. Total body PET/CT technology is an ideal tool to evaluate biodistribution and dosimetry of new PET radiopharmaceuticals in our first human studies.' Knowing the potential of this technology, researchers at Stanford Medicine and engineers at GE HealthCare aim to advance a next-generation PET/CT designed to provide new opportunities to improve diagnosis, staging, therapeutic planning, and evaluation of treatment response across various care pathways. By leveraging the technology's capabilities, both institutions believe it has the potential to drive new clinical pathways, expedite the development and translation of new diagnostic and therapeutic agents, support existing molecular imaging and theranostics applications, and promote enhanced healthcare system efficiency. 'The high throughput we anticipate from this technology could ultimately help improve access for our patients and reduce wait times to their next appointment,' says Dr. Erin Grady, incoming Division Chief of Nuclear Medicine and Molecular Imaging, Stanford Medicine. GE HealthCare's total body PET/CT innovation In collaboration with a select group of leading healthcare institutions around the world, GE HealthCare aims to demonstrate how total body PET/CT imaging can overcome barriers that previously hindered widespread adoption of PET/CT beyond oncology. This initiative seeks to expand the use of PET with the goal of leveraging ultra-high sensitivity total body PET/CT technology to push the boundaries of oncology by significantly reducing scan time and the injected dose – important considerations for all patients, but particularly vulnerable patients like pediatrics, where ultra-fast scans can allow reduction in anesthesia and sedation in children. To support this advanced research, encourage new discoveries, and meet growing clinical demands, GE HealthCare designed its total body PET/CT technology with the goal of enabling ultra-low dose scans; fast acquisitions; multi organ dynamic imaging; and dual tracer imaging. All important factors that help improve diagnosis confidence. In parallel, the technology aims to improve healthcare system efficiency by enhancing clinical workflows, supporting routine clinical practice, and improving operational efficiency. 'At GE HealthCare, innovation is in our DNA. Our total body PET/CT technology represents the next chapter in our enduring commitment to advancing medical imaging,' adds Jean-Luc Procaccini, President & CEO, Molecular Imaging and Computed Tomography, GE HealthCare. 'We're proud to collaborate with world-class institutions to explore new clinical frontiers in oncology and beyond. Together with our MIM software solutions, we're designing flexible, AI-enhanced tools that not only aim to enhance diagnostic confidence and operational efficiency but also help clinicians deliver more precise, personalized care that can truly improve patient outcomes.' GE HealthCare has a long-standing history of and commitment to pioneering next-generation imaging technology. From the first commercially available PET/CT solution, Discovery LS, ii to the development of the first silicon-based photon counting computed tomography (CT) prototype, iii GE HealthCare continues to push the boundaries of medical imaging for the benefit of clinicians and patients worldwide. As such, GE HealthCare is at the forefront of driving a connected healthcare transformation and revolutionizing precision care. For more information on GE HealthCare's impressive Molecular Imaging portfolio, visit About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™.


Business Wire
an hour ago
- Business Wire
Poxel SA: New Scientific Presentations by Key Opinion Leaders to Further Highlight the Therapeutic Potential of Imeglimin at ADA 2025, the Leading Diabetes Conference
LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including Metabolic dysfunction-Associated SteatoHepatitis (MASH) and rare metabolic disorders, today announces that five presentations in relation to the potential of Imeglimin, marketed under the brand name TWYMEEG ® in Japan, will be made at the 85 th Scientific Sessions of the American Diabetes Associations, from June 20 to 23, 2025, in Chicago, Illinois (U.S.A). A total of 5 publications, including results from 2 clinical trials and 3 non-clinical studies supported by Sumitomo Pharma, will be delivered by leading Japanese diabetes experts. Main topics include: Potential of Imeglimin to Improve Inflammation and Fibrosis in Diabetic Kidney Disease, by Yoshimi Muta, from Fukuoka University (Fukuoka, Japan) The Efficacy of Imeglimin and Metformin on Insulin Sensitivity and Secretion Using Oral Minimal Model, by Ryota Usui, from Kansai Electric Power Hospital (Osaka, Japan) Attempts to Identify Predictors of Glycemic Control with Imeglimin—Machine Learning Analysis Using Clinical Trial Data, by Katsuhiko Hagi, from Sumitomo Pharma Therapeutic Potential of Imeglimin for Diabetic Neuropathy—Neuroprotective Effects in Type 1 Diabetic Rats, by Wataru Nihei, from the Aichi Gakuin University School of Pharmacy's Laboratory of Medicine (Nagoya, Japan) Effect of Imeglimin on Periodontitis in Streptozotocin-Induced Diabetic Rats, by Shun Kondo, from the Aichi Gakuin University's School of Dentistry (Nagoya, Japan) Thomas Kuhn, CEO of Poxel, stated: 'We are very pleased to see that the potential of Imeglimin (TWYMEEG ®) in the fight against type 2 diabetes and its associated conditions continues to generate enthusiasm within the scientific community, with the support of our partner Sumitomo Pharma. The presentations on TWYMEEG ®, at the world's most important academic event on diabetes provide further confirmation of its value as a treatment for diabetic patients.' About Poxel SA Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare disorders. For the treatment of MASH, PXL065 (deuterium-stabilized R -pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG ® (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan. For more information, please visit: All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as 'target,' 'believe,' 'expect,' 'aim,' 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is not otherwise responsible for the content of external hyperlinks referred to in this press release.